CALL TO ACTION
A unique opportunity for patients and experts to inform and educate the FDA about the effects of their disease and the need for new treatments.
There are currently no treatments that are approved by the FDA for any of the amyloidosis diseases. With a number of promising treatments in development, there is a pressing need for these to be safely and quickly evaluated. The patient voice is a critical part of the research process.
We need your participation!
Join us and make a difference.
The FDA has requested that we hold this meeting. We need patients, caregivers and their advocates to demonstrate their support by participating on November 16th.
This event will be held at the DoubleTree by Hilton Hotel in Silver Spring, MD on November 16th, 9:00 a.m. to 3:00 p.m.
This event is hosted by the Amyloidosis Research Consortium (ARC) in collaboration with the Amyloidosis Foundation and Amyloidosis Support Groups.
The ARC is focused on advancing effective treatments for systemic amyloidosis. The ARC brings together researchers, advocates, industry, and government regulators with a common goal. Through our collaborative model we expedite the delivery of treatments that matter to patients. As a patient-driven organization, we are fully committed to improving outcomes and delivering results.
The Amyloidosis Research Consortium, Inc. is a 501(c)(3) nonprofit organization. Learn more about us at www.arci.org.
Any questions, please contact us at [email protected].